Current Pipeline
At Isosceles, our aim is to provide an opioid alternative with access to as many patients as possible and pledge to be a part of the solution addressing unmet medical needs in postoperative pain space. This policy ensures the safety of our products through rigorous R&D testing and compliance with all FDA guidelines.


Synthetic cannabidiol-based Intravenous injection

Acute post operative pain
Phase 1
Phase 2
Phase 3
Regulatory Review


Investigational drug product candidate  –    IPI201
Isosceles has pioneered a proprietary intravenous formulation based on our synthetic cannabidiol through a patented cGMP-compliant synthetic manufacturing process. IPI201 is a highly bioavailable parenteral formulation that has undergone rigorous analytical testing methods and adheres to the highest quality standards.
Investigational drug product candidate - IPI301
Isosceles is in late-stage development with its exclusive microneedle partner to develop a dissolving microneedle capable of needle-free, intradermal delivery. Our partners have developed a sharps-free platform for vaccines that Isosceles utilizing and modifying in development of a rapid onset, site specific pain relief product.
Copyright © 2022 · Isosceles Pharmaceuticals, Inc.